Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Asthma drug found highly effective in treating chronic, severe hives and itch

25.02.2013
Omalizumab therapy could soon replace other, more toxic treatments

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash.

The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

"Physicians and patients may now have a fast, safe and well-tolerated treatment option to consider before prescribing even more antihistamines, which can be highly sedating," says Sarbjit (Romi) Saini, M.D., a Johns Hopkins allergist and immunologist, and study co-investigator. The research team's findings are scheduled to be published in The New England Journal of Medicine online Feb. 24, to coincide with their initial presentation at the annual meeting of the American Academy of Allergy, Asthma & Immunology in San Antonio, Texas.

Participants in the study, which ran from 2009 to 2011, were mostly women and between the ages of 12 and 75. Each was randomly assigned to take one of three dosing regimens of omalizumab, or placebo, after which they were monitored through regular checkups for four months. Neither researchers nor participants were aware of what specific dose was being taken by which subjects during the study.

All study participants had chronic hives and rash for at least six months, with many having suffered from the condition for more than five years. All had continued to experience hives or a severe itchy rash for a full week while taking antihistamines.

"Patients suffering with this condition need more and better treatment options because chronic hives and rash are profoundly hard to treat and can be very debilitating," says Saini, an associate professor at the Johns Hopkins University School of Medicine. Saini, who has studied omalizumab since 2005, points out that fewer than half of those treated respond to traditional drug treatments with antihistamines.

Saini says the new study results offer substantial evidence that this first injection treatment option not only works, but does so more safely than other drugs, such as corticosteroids and the immunosuppressant cyclosporine, which carry risk of potentially severe and toxic side effects, including high blood pressure, bone thinning and even infection. By contrast, headache was the most severe side effect observed with omalizumab therapy. No study participants died or suffered anaphylactic shock, or had to withdraw because of any adverse effects or events.

According to Saini, chronic idiopathic urticaria affects some 3 million Americans, and may or may not involve swelling, with twice as many women as men suffering from these often socially isolating conditions. Saini says some patients experience such severe swelling of their eyes, hands, face, lips and throat that they have difficulty breathing. Some refuse to leave home, losing several days at a time away from work during flare-ups.

In the study, the team of American and European researchers injected a 300-milligram dose of the drug, sold under the brand name Xolair, once a month for three months. Saini says initial relief from symptoms was quick and occurred after a week. After three months, 53 percent of people experienced a total elimination of all hives and 44 percent had no further incidents of hives or itch. Lower doses of the drug, at 150 milligrams and 75 milligrams, and the placebo (or 0 milligrams) proved half as effective as the next larger dose, or had almost no effect at all, researchers say.

Saini, who also serves as director of Johns Hopkins' medical fellowship training program in allergy and clinical immunology, had conducted earlier research on the test doses, which he says are different from those used in omalizumab therapy for asthma. Single, uniform doses of omalizumab can be used to treat hives, whereas dosing for asthma is calculated based on the patient's weight and blood levels of IgE antibodies, known to play a key role in allergic reactions.

Researchers say it remains unclear as to precisely how omalizumab, first approved in the United States in 2003 as a treatment for severe asthma, stops the runaway allergy-like reactions underpinning chronic hives and itching. What is known, he says, is that omalizumab binds up free IgE circulating in the body, and lowers the number of IgE receptors on other histamine-carrying immune system cells. Saini says that in a typical allergic reaction, allergens, such as pollen and dust particles, bind to IgE receptors that sit on these immune system cells. This process quickly results in a controlled, wave-like release of histamine, a key triggering chemical involved in inflammation. But in the itchy rash of chronic hives, histamine release appears to be more spontaneous, suggesting that the histamine-carrying mast cells and basophils are abnormal.

Saini next plans more studies on omalizumab's effects on IgE, and how it contributes to chronic hives and rash. He says his goal is to understand the underlying mechanism of the disease and explain why the drug is effective.

Saini is a paid consultant to both Genentech and Novartis, omalizumab's marketer and manufacturer, respectively, which funded the latest study. The terms of these arrangements are being managed by The Johns Hopkins University in accordance with its conflict-of-interest policies.

Besides Saini, other researchers involved in this study were lead investigator Marcus Maurer, M.D., at the Charité-Universitätsmedizin in Berlin, Germany. Study co-investigators included Karin Rosen, M.D., Ph.D.; Hsin-Ju Hsieh, Ph.D.; Sunil Agarwal, M.D.; and Ramona Doyle, M.D., at Genentech Inc., in San Francisco, Calif.; as well as Clive Grattan, M.D., at Norfolk and Norwich University Hospital in Norwich, United Kingdom; Ana Gimenez-Arnau, M.D., Ph.D., at the Universitat Autònoma in Barcelona, Spain; and Janice Canvin, M.D., at Novartis AG in Redhill, United Kingdom; Allen Kaplan, M.D., at the Medical University of South Carolina in Charleston; and senior study investigator Thomas Casale, at Creighton University Medical Center in Omaha, Neb.

For more information, go to:

http://www.hopkinsmedicine.org/allergy/faculty/saini.html
http://www.nejm.org/
http://annualmeeting.aaaai.org/

David March | EurekAlert!
Further information:
http://www.jhmi.edu

More articles from Health and Medicine:

nachricht New vaccine production could improve flu shot accuracy
25.07.2017 | Duke University

nachricht Chances to treat childhood dementia
24.07.2017 | Julius-Maximilians-Universität Würzburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Carbon Nanotubes Turn Electrical Current into Light-emitting Quasi-particles

Strong light-matter coupling in these semiconducting tubes may hold the key to electrically pumped lasers

Light-matter quasi-particles can be generated electrically in semiconducting carbon nanotubes. Material scientists and physicists from Heidelberg University...

Im Focus: Flexible proximity sensor creates smart surfaces

Fraunhofer IPA has developed a proximity sensor made from silicone and carbon nanotubes (CNT) which detects objects and determines their position. The materials and printing process used mean that the sensor is extremely flexible, economical and can be used for large surfaces. Industry and research partners can use and further develop this innovation straight away.

At first glance, the proximity sensor appears to be nothing special: a thin, elastic layer of silicone onto which black square surfaces are printed, but these...

Im Focus: 3-D scanning with water

3-D shape acquisition using water displacement as the shape sensor for the reconstruction of complex objects

A global team of computer scientists and engineers have developed an innovative technique that more completely reconstructs challenging 3D objects. An ancient...

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA mission surfs through waves in space to understand space weather

25.07.2017 | Physics and Astronomy

Strength of tectonic plates may explain shape of the Tibetan Plateau, study finds

25.07.2017 | Earth Sciences

The dense vessel network regulates formation of thrombocytes in the bone marrow

25.07.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>